Who We Are
Neurxstem develops the first and only patented functional human brain model capable of delivering regulator-grade molecular data for discovery, diagnostics, therapeutics, and predictive AI. Our work is grounded in human biology, precision functional genomics, and multi-omic reproducibility.
The platform was designed to address a longstanding gap in medicine: the inability of animal systems to predict human disease or therapeutic response.
By reconstructing the genomic and metabolic circuitry of the human brain, Neurxstem provides a foundation for translational certainty across neurological, aging, and chronic disease programs.
Our Origin Story
Neurxstem began as both a scientific and humanitarian pursuit. Through years of work with autism advocacy groups, Dr. Rene Anand focused his research on how genetics, nutrition, and environmental exposures interact to influence susceptibility, development, aging, and disease in the human brain.
Rodent systems could not model these interactions.
They cannot reproduce human ancestry, sex-based differences, diet, microbiome composition, or the gene–environment dynamics that drive neurological and age-related conditions. This mismatch contributed to decades of failed CNS drug translation and highlighted the need for a human-specific foundation.
Addressing this required creating a platform capable of modeling how gene regulatory networks and metabolic pathways respond to nutritional state, environmental variables, and genetic background across time—a system aligned with human biology rather than an approximation of it.
This work resulted in a sequence of milestones:
In 2015, this research led to the creation of the first complete human brain model containing all major regions and principal cell types.
In 2016, the technology received its U.S. patent.
In 2023, the FDA Modernization Act established human evidence as the standard for preclinical validation—confirming a trajectory Neurxstem had pursued nearly a decade earlier.
Today, the platform provides the biological resolution necessary to follow how nutrition, environment, genetics, and aging interact across the entire human lifetime at the molecular level, supporting early diagnostics, mechanism-of-disease research, therapeutic development, and predictive AI.
Our Platform
The Neurxstem Neural Organoid Platform (NNOP™) is a multi-regional human brain model engineered to reproduce the architecture, genomic circuitry, and cell-type composition of the human brain. Derived from reprogrammed human skin cells, it includes all major regions—from the retina and cortex to the midbrain, hindbrain, cerebellum, spinal cord, and blood–brain barrier—along with neurons, astrocytes, oligodendrocytes, vascular endothelial cells, and microglia.
The platform delivers:
15,000+ gene-expression datapoints per model
High-resolution, regulator-grade transcriptomic signatures.98–99% reproducibility across lines and replicates
Consistent molecular patterns across independent cell lines.p < 10⁻¹⁰⁰ concordance with clinical Alzheimer’s tissue
Direct alignment with postmortem human molecular profiles.Matched transcriptomic and metabolomic data
High-field NMR and multi-omic integration enabling precise, reliable inputs for AI development.
Neurxstem’s platform has been validated through federally funded research programs, including NIH and Department of Defense studies, and aligns with the FDA Modernization Act requirements for human-relevant preclinical evidence.
Intellectual Property
Neurxstem’s platform is protected by an issued U.S. patent and an expanded portfolio of provisional patents covering diagnostics, therapeutics, aging models, and AI applications.
Issued U.S. Patent
The patent encompasses:
A fully integrated human neural organoid model across all major brain regions
Inclusion of microglia and vascular components
Functional genomic circuitry reflective of human development and disease
Applications in disease modeling, drug screening, biomarker identification, and mechanistic interrogation
This is the first and only patent of its kind.
Provisional Patent Portfolio
Neurxstem’s provisional filings extend protection across:
Therapeutics: Alzheimer’s, Parkinson’s, aging, migraine
Diagnostics: Early biomarkers and companion assays
Aging: Progeria-based accelerated aging models reproducing the hallmarks of aging
AI Healthcare: Big-omics data for predictive analytics, prodromal tracking, digital twins, and clinical decision support
This portfolio establishes a defensible scientific and commercial foundation.
Scientific Validation
Neurxstem’s models and molecular signatures have been validated through independent federally funded research, including NIH and Department of Defense programs.
The platform’s reproducibility metrics, disease-specific gene expression patterns, and metabolomic signatures align with peer-reviewed findings across Alzheimer’s, Parkinson’s, aging, and neurodevelopmental conditions.
The datasets meet the rigor expected under the FDA Modernization Act, supporting human-relevant, regulator-aligned evidence for future clinical translation.
Location & Research Ecosystem
Neurxstem is based at the Central Ohio Aerospace Research & Technology Center, an environment supporting advanced biomedicine, engineering, and computational research.
The company collaborates with scientific advisors across neuroscience, genomics, pharmacology, AI, and clinical medicine.